Compare ARK Genomic Revolution ETF (ARKG) vs Dolby Laboratories, Inc. (DLB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Dolby Laboratories, Inc. — how do they compare? ARK Genomic Revolution ETF trades at $40.95, while Dolby Laboratories, Inc. trades at $50.11 (market cap $4.71B). The key difference: Dolby Laboratories, Inc. pays a 2.83% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Dolby Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| ARKG | DLB | |
|---|---|---|
Sector | Sector/Thematic | Industrials |
52-Week High | $43.57 | $76.79 |
52-Week Low | $23.09 | $49.31 |
Market Cap | — | $4.71B |
Enterprise Value | — | $4.17B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
DLB trades at $49.8, down 0.64% on the day, with a bearish technical outlook but strong fundamentals. Recent earnings beats, including Q1 2026 EPS of $1.37 versus $1.31 expected, highlight operational strength. The company maintains high gross margins of 87.44% and positive cash flow, supported by licensing growth and expanding Dolby Atmos adoption.
The stock presents a value opportunity with a P/E of 19.76 below historical averages, and a consensus price target of $87.50 implies significant upside. Risks include cyclical end-market exposure and potential dilution from pipeline developments. Analyst sentiment is moderately bullish, but technical indicators suggest near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →
